SUMMARY Growth hormone and prolactin response to levodopa were evaluated before and after long-term phenytoin treatment in five men with previously untreated partial epilepsy. After phenytoin treatment, growth hormone response to levodopa increased. There was a close relationship between growth hormone response to levodopa and plasma phenytoin concentrations. These findings suggest a phenytoin-induced dopaminergic activity at the hypothalamic-pituitary level in adult males.
Recently, Luoma et al' reported elevated serum growth hormone (GH) levels in women treated with phenytoin and carbamazepine. London et al,2 however, reported lowered response of growth hormone to insulin hypoglycaemia, unchanged baseline growth hormone levels, and increased prolactin response to thyrotropin-releasing hormone administration in healthy male volunteers after 7 days of treatment with phenytoin or carbamazepine. Such hormonal changes may be due to interaction of phenytoin or carbamazepine with the monaminergic systems that control hypothalamic-pituitary function. 3 Clinical findings indirectly suggest that phenytoin may interact with the dopaminergic system at the striatal level.4 Furthermore, both in vivo and in vitro laboratory studies indicate that phenytoin changes the dopaminergic activity within the central nervous system. Hadfield5 showed that dopamine uptake is inhibited by phenytoin in the striatum but stimulated in the hypothalamus; Elliott et a16 found that phenytoin reduced dopamine utilisation and induced a neuroleptic-like activity in behavioral tests on mice. Lepore et aP suggested that phenytoin may act as a dopaminergic agonist, since it reduces dopamine turnover in rat striatum.
In the present study, we evaluated growth hor-tic men before and after long-term administration of phenytoin to determine if the treatment had any effect on hypothalamic-pituitary regulation.
Subjects and methods
The study was performed on five epileptic men (22 to 49 years of age) who had less than a 6 month history of previously untreated cryptogenetic partial epilepsy. All patients gave their informed consent to the study. Plasma prolactin and growth hormone concentrations were determined in duplicate by radioimmunoassay, using a commercially available kit (Biodata, Serono, Italy). The method is sensitive to 1-0 ng/ml for prolactin and 0-25 ng/ml for growth hormone. Plasma phenytoin concentrations were measured by a gas chromatographic method.8
In two patients, the oral dose of phenytoin was increased on the basis of low plasma phenytoin concentrations, and the levodopa test was repeated after 1 month. Thereafter, phenytoin was further increased in one patient and the levodopa test was repeated again 1 month later. (For these two patients, the data reported in tables 1 and 2 refer to 715 D'Alessandro, Cortelli, Gallassi, Ghisoli, Montanaro, Zoni, Baruzzi the levodopa test obtained at the higher plasma phenytoin concentrations).
Statistical analysis Serum prolactin and growth hormone concentration values (ng/ml) underwent two separate analyses of variance (ANOVA) according to a 2 x 7 x 5 design (phenytoin x times of levodopa administration x subjects). Data were submitted to log-transformation in order to achieve the condition of homogeneity of "error" variances. If the interaction "phenytoin treatment x times of levodopa administration" was significant, ANOVA was followed by single contrasts "before vs after phenytoin" at each of the seven times of the levodopa test.' Further, the relationship between plasma phenytoin levels and growth hormone peak response to levodopa was evaluated by linear regression analysis. The analysis was performed on the differences between the peak growth hormone value obtained before and after antiepileptic drug treatment; eight differences were evaluated since two of the five subjects had more than one test.
Results
GROWTH HORMONE RESPONSE TO LEVODOPA TEST Table 1 shows the individual values obtained at each of the seven levodopa test times before and after 1 month of phenytoin treatment; the table also contains the mean (+SEM) on the original scale (ng/ ml). ANOVA of log-transformed values yielded a highly significant interaction "phenytoin treatment x times of levodopa test" (F = 3-296; DF = 6/52; p < 0-01), indicating that growth hormone response exhibited a different trend after phenytoin treatment. Single "before vs after" contrasts (see Table  1 Table 2 shows the single values obtained from the observations as well as the means (± SEM) on the original scale (ng/ml). As in growth hormone response, ANOVA of log-transformed values yielded a significant interaction "phenytoin treatment x times of levodopa test' (F = 2-766; DF = 6/52; p < 0-025), indicating that prolactin response to levodopa also displayed a different pattern after phenytoin treatment. In this case, too, "before vs after" contrasts (see table 2) did not show any difference in baseline values at -15 and 0 test times, but revealed changes in the response to dopaminergic stimulation after phenytoin therapy. The mean prolactin values were lower at 120 and 180 min after levodopa administration.
Discussion
Our study showed that chronic phenytoin administration enhanced growth hormone and prolactin responses to levodopa. However the effect of phenytoin on prolactin response, although statistically significant, must be considered with caution since the magnitude of the differences in prolactin levels 
